NCT01078142 - Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2010

Primary Completion Date

September 8, 2017

Study Completion Date

September 8, 2017

Conditions

Follicular LymphomaMantle Cell Lymphoma

Interventions

DRUG

Temsirolimus, Rituximab, Bendamustin

"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"

Trial Locations (1)

55131

Universitätsmedizin Mainz, Mainz